Background: HX575 (biosimilar epoetin alfa) was approved in Europe in 2007 for the treatment of chronic kidney disease (CKD)-related anemia. This study assessed the clinical equivalence of HX575 with the US-licensed reference epoetin alfa (Epogen ® /Procrit ® , Amgen/Janssen) following subcutaneous (SC) administration in dialysis patients with CKD-related anemia. Methods: This randomized, double-blind, parallelgroup, multicenter study (NCT01693029) was conducted at 49 US clinical sites. Eligible patients were aged ≥18 years, had end-stage renal disease, were on hemodialysis or peritoneal dialysis for ≥6 months (or ≥12 months in the case of a failed kidney transplant), and were receiving treatment with stable SC doses of epoetin alfa. Eligible patients also had mean hemoglobin (Hb) concentration between 9.0 and 11.5 g/dL during the screening period. The primary endpoint was the mean absolute change in Hb concentration between the screening/baseline period (week-4 to week-1) and the evaluation period (weeks 21 to 28). Results: Hb values at the end of the evaluation period and the Hb change from baseline to evaluation period were similar between treatment groups. The estimated difference between groups in mean absolute change in Hb concentration was -0.093 g/dL, with 90% CI (-0.23 to 0.04) entirely within the pre-specified equivalence limits (-0.5 to 0.5 g/dL). The safety profile of each medicine was similar and as expected in dialysis patients, and neither method of treatment led to the development of neutralizing, clinically relevant antibodies. Conclusions: SC HX575 in dialysis patients with renal anemia was therapeutically equivalent to the reference medicine in terms of maintaining stable Hb levels and safety.
Introduction

HX575 (biosimilar epoetin alfa; Binocrit
® , Hexal AG) was approved in Europe in 2007 for the treatment of chronic kidney disease (CKD)-related anemia. The initial approval of HX575 was for intravenous (IV) administration, which was in accordance with the label of the reference medicine at that time. More recently, a multinational, open-label, single-arm, phase III European study was conducted to evaluate the safety and immunogenicity of subcutaneous (SC) HX575 in CKD-related anemia in pre-dialysis and dialysis patients [1] . SC use of HX575 was found to be efficacious and well tolerated. Based on these data, the SC administration of HX575 was approved by the European Commission in March 2016 [2] .
Here we report the results of a randomized, doubleblind, efficacy and safety study (the ACCESS study, A Clinical Research Study in Chronic Kidney Disease and Anemia) conducted in the United States (US), which aimed to show clinical equivalence of HX575 with the USlicensed reference epoetin alfa (Epogen ® /Procrit ® , Amgen/Janssen) following SC administration in dialysis patients with anemia of CKD.
Methods
The study was a randomized, double-blind, parallel-group, multicenter study (NCT01693029) in which patients were enrolled at 49 US clinical sites. The relevant Institutional Review Boards approved the protocol and the trial was conducted in accordance with the Declaration of Helsinki International Council for Harmonisation Good Clinical Practice and any applicable local regulations. All analyzed patients provided written, informed consent.
Male and female patients aged 18 years or older were eligible if they had end-stage renal disease and were on hemodialysis or peritoneal dialysis for at least 6 months (or at least 12 months in the case of a failed kidney transplant). All patients had to be receiving treatment with stable (≤30% change in weekly dose during screening) SC doses of epoetin alfa administered at least once per week, with a maximum weekly dose of 300 IU/kg. Eligible patients had mean hemoglobin (Hb) concentration between 9.0 and 11.5 g/dL during the screening period (samples were collected prior to the dialysis session, preferably in the middle of the week), and had adequate iron substitution (serum ferritin ≥200 μg/L and transferrin saturation ≥20%, confirmed by a sample collected at the time of first screening).
Main exclusion criteria included the history of pure red cell aplasia or anti-erythropoietin antibodies; lack of efficacy or loss of effect with a previous erythropoiesis-stimulating agent (ESA) therapy; and positive result for binding anti-erythropoietin antibodies during screening. Eligibility was assessed during a 4-week screening period, after which patients entered a 52-week treatment period. The SC administration of epoetin alfa (HX575 and the USlicensed reference epoetin alfa) was requested by the US Food and Drug Administration.
Study Design
Patients were randomized 1: 1 by an interactive response technology to SC HX575 or reference epoetin alfa. Unless a dose adjustment was medically indicated at the baseline visit, the initial weekly dose and dosing frequency of study treatments were the same as the weekly dose and dosing frequency of epoetin alfa prior to randomization. During treatment, the dose was individually titrated to maintain Hb levels in the target range 10.0-11.0 g/dL. The primary endpoint was the mean absolute change in Hb concentration between the screening/baseline period (week-4 to week-1) and the evaluation period (weeks 21 to 28). The primary analysis was performed in the intention to treat population, which consisted of all randomized patients who were exposed to treatment with study drug for ≥4 weeks and had ≥1 Hb value available at week 4 or later. The estimated difference in Hb levels between the groups was determined by analysis of covariance (ANCOVA). Treatment was included as a factor and the covariates were mean baseline Hb and mean weekly dose during the evaluation period. HX575 would be considered equivalent to the reference medicine if the 2-sided 90% CI resided entirely within the equivalence limits of -0.5 to 0.5 g/dL. It was planned to randomize at least 360 patients to maintain at least 320 evaluable patients (randomized 1: 1 to HX575 and the reference medicine) to have 90% power to reject the null hypothesis that treatment with HX575 was not equivalent to the reference medicine.
Secondary endpoints included the incidence of antibody formation against epoetin (anti-erythropoietin binding antibodies and neutralizing antibodies), overall safety profiles, and epoetin dose. The safety population consisted of all patients who were randomized and received ≥1 dose of study drug. The evaluation of the immune response was based on a validated, highly sensitive antierythropoietin antibody-binding radioimmunoprecipitation (RIP) assay and validated cell-based neutralizing antibody assays performed at the sponsor's laboratory.
Results
A total of 835 patients were screened, of whom 437 were randomized (online suppl. material, Fig. S1 ; for all online suppl. material, see www.karger.com/ doi/10.1159/000481736). Two patients were treated but excluded from any analyses due to informed consent issues; the remaining 435 comprised the safety population. In total, 210 patients treated with HX575 and 212 patients treated with the reference medicine were included in the intention to treat population and were analyzed for the primary endpoint.
Baseline demographic and clinical characteristics were similar between the treatment groups (Table 1) . Overall, the mean (SD) age was 58.7 (13.6) years and 57.5% of patients were male. The primary cause of CKD was diabetes (HX575, 53.0%; reference medicine, 56.0%), followed by hypertension (HX575, 30.0%; reference medicine, 23.9%) and chronic glomerulonephritis (HX575, 6.0%; reference medicine, 7.3%).
Efficacy
At baseline, the mean (SD) Hb concentration was 10.53 (0.64) g/dL in the HX575 group and 10.50 (0.62) g/dL in the reference medicine group (Table 2) . Hb values at the end of the evaluation period and the Hb change from baseline to evaluation period were similar between treatment DOI: 10.1159/000481736 Fig. 1 ). The estimated difference between groups in mean absolute change in Hb concentration was -0.093 g/dL, with 90% CI (-0.23 to 0.04) entirely within the pre-specified equivalence limits (-0.5 to 0.5 g/dL); therefore, the primary endpoint of the study was met.
Epoetin Dose
The mean (SD) epoetin dose in the HX575 group was 7,761 (9,488) IU at week 1, 5,877 (5,786) IU during the evaluation period (week 21 to 28), and 6,054 (8,381) IU at week 52. For the reference medicine group, the mean (SD) epoetin dose was 6,662 (6,447) IU at week 1, 5,840 (6,065) IU during the evaluation period (weeks 21 to 28), and 4,440 (5,315) IU at week 52. The mean weekly epoetin dose tended to be higher in the HX575 group than in the reference medicine group; this difference was present at the beginning of the study (i.e., after conversion from the pre-study ESA treatment) and the trend continued throughout the study.
Safety
The most frequently reported treatment-emergent adverse events (TEAEs) were hypertension (HX575, 11.5%; reference medicine 13.3%), diarrhea (HX575, 10.1%; reference medicine, 8.7%), hyperkalemia (both groups, 9.2%), and nausea (HX575, 7.8%; reference medicine, 9.6%). In total, 5 (2.3%) patients in the HX575 group and 11 (5.0%) in the reference medicine group reported TEAEs considered by investigators to be related to the study drug (online suppl. material, Table S1 ).
Four (0.9%) patients experienced 5 treatment-emergent serious AEs (SAEs) that were considered related to treatment. In the HX575 group, 3 (1.4%) patients experienced 4 related treatment-emergent SAEs (cerebrovascular accident, ischemic stroke, myocardial infarction, and worsening of anemia), while in the reference medicine group, there was one (0.5%) case of congestive cardiac failure considered related to treatment. Thromboembolic events and de-novo malignancies were categorized as TEAEs of special interest. The incidence of thromboembolic events (including dialysis access thrombosis) was similar between the 2 treatment groups (HX575, 35 [16.1%] patients and 45 events; reference medicine, 36 [16.5%] patients and 54 events). Malignancies were reported more frequently for the reference medicine group (9 patients [4.1%] vs. 4 patients [1.8%] in the HX575 treatment group); however, the absolute number of events was very low in general (10 vs. 4 events, respectively). Five patients in the HX575 group and 11 in the reference medicine group died during the treatment phase (up to 30 days after last dose) due to TEAEs. In both treatment groups, the most common TEAEs leading to death were conditions associated with the System Organ Class Cardiac Disorders (n = 5 in each group). The other TEAEs leading to death in the reference medicine group where chronic renal failure, azotemia, endocarditis/cerebrovascular acci- dent, bladder cancer, acute respiratory failure and cachexia (all n = 1). No causal relationship with the study drug was suspected in any of the TEAEs leading to death. The number of patients who reported procedural pain was similar in the HX575 group (1/217) and the reference medicine group (4/218). All of these TEAEs were reported as mild or moderate in intensity.
Immunogenicity
Nine patients tested positive for binding anti-erythropoietin antibodies by RIP assay (Table 3 ; 7 patients in the HX575 group and 2 in the reference medicine group). This includes 2 patients (1 patient from each treatment arm) who tested negative at the first screening assessment but tested positive at the baseline assessment (sample taken before any administration of study drug). Both of these patients were discontinued from treatment (as per protocol) when the results of the baseline assessment became available. Thus, treatment-emergent binding anti-erythropoietin antibodies were detected in 7 patients (6 [2.8%] in the HX575 group and 1 [0.5%] in the reference medicine group) at timepoints ranging from 112 to 340 days. Treatment duration-related incidence rates of anti-erythropoietin antibodies were 0.036 (HX575) and 0.011 (reference medicine; Table 3 ). Titers of RIP anti-erythropoietin antibodies were low and fluctuating, and all 7 patients who tested positive in the RIP assay at one point during the study had at least one subsequent negative RIP assay result. None of these patients developed neutralizing anti-erythropoietin antibodies at any time.
The occurrence of binding but non-neutralizing antierythropoietin antibodies was neither found to be associated with AEs during the study period and for 30 days following study discontinuation nor found to have any impact on efficacy in the study period and the subsequent safety follow-up. There were no clinical signs of immunogenicity or hypersensitivity during the 12-month treatment period.
Discussion
The double-blind, comparative ACCESS study met its primary objective and demonstrated that SC administration of HX575 in patients on dialysis with renal anemia was therapeutically equivalent to the reference epoetin alfa administered SC in terms of maintaining stable Hb levels. In addition to comparable efficacy, HX575 and the reference epoetin alfa demonstrated a similar safety profile, which was also consistent with that expected for treatment with epoetin alfa in patients on dialysis. Furthermore, SC administration of HX575 or the reference medicine did not elicit the development of neutralizing or otherwise clinically relevant antibodies during the 12-month study period and during the subsequent safety follow-up (at least 6 months).
These findings are consistent with those from an openlabel single-arm, phase III European study, which found that SC HX575 maintained stable Hb levels in 416 dialysis-and non-dialysis-dependent adult patients with CKD [1] . Also in the European study, no patient developed neutralizing antibodies and anti-erythropoietin antibodies were mainly transient despite the fact that all patients who tested positive for anti-drug antibodies remained in the study and continued treatment with SC HX575. In contrast, patients in the ACCESS study were discontinued if they tested positive in the RIP assay, in accordance with the study protocol.
The proportion of patients in ACCESS who tested positive for anti-erythropoietin antibodies after study drug administration is similar to that in the European SENSE study (Safety Evaluation in Nephrology of Subcutaneous Epoetin) [1] ; it is also consistent with other data from the literature on the development of binding, non-neutralizing antibodies following ESA treatment in clinical studies [3] . In ACCESS, the titers of RIP anti-erythropoietin antibodies were low and fluctuating. All 7 patients who tested positive in the RIP assay at one point during the study had at least one subsequent negative RIP assay result, and some patients alternated between positive and negative RIP assay results. These observations, together with the highly sensitive RIP assay used (a potential 1% false-positive rate), indicate that there was no sustained, clinically relevant anti-drug antibody response in any patient.
In the current ACCESS study, patients randomized to HX575 received a slightly higher starting dose than those randomized to the reference medicine, and this trend continued throughout the study treatment period. The double-blind nature of the study treatment excludes the role of investigator bias in administering higher doses in the HX575 arm from the start. The higher doses of HX575 throughout the study treatment period are unlikely to be due to decreased effectiveness compared with the reference medicine, given that the dose difference was evident from the start of treatment. There is also no evidence of the need for higher doses when switching to biosimilar ESAs, based on other published data. A large (n = 1,695 patients with CKD) post-approval study of HX575 administered IV was conducted to monitor AEs in clinical practice, and also assessed the efficacy of HX575 after conversion from a range of pre-study ESAs [4] . Target Hb levels were maintained effectively after patients were switched to IV HX575. The dose of HX575 was stable in those patients switched from previous IV ESA treatment, with a significant (but expected) 13% dose increase in patients switched from prior SC ESA treatment. Another study investigated differences between originator and biosimilar (HX575 and SB309 [epoetin zeta]) ESA utilization based on defined daily doses, doses upon switching, differences between short-and long-acting ESAs and prescribed daily doses in ambulatory patients (n = 6,117) with renal anemia undergoing chronic maintenance hemodialysis [5] . In this population-based analysis of real-world data, doses were not increased when the therapy was switched from the originator to a biosimilar ESA. Moreover, in 1,886 patients receiving a continuous prescription over 12 accounting quarters, patients receiving short-acting originator ESAs, long-acting darbepoetin alfa and biosimilar ESAs had a similar median defined daily doses consumption (0.80, 0.86, and 0.81, respectively) [5] .
The ratio of weekly ESA dose of Hb level for each treatment group was not part of the pre-specified primary and secondary analyses. However, the primary analysis showed that Hb level (within the observation period, weeks 21-28) was the same for each group when adjusted for weekly dose. No assessment of HX575 and the reference epoetin alfa was performed according to dialysis type, given the small number of patients in each group who were in receipt of peritoneal dialysis (HX575, 25/217; reference epoetin alfa 26/218).
In summary, SC administration of HX575 in patients on dialysis with renal anemia was therapeutically equivalent to the reference epoetin alfa in terms of maintaining stable Hb levels. SC administration of HX575 and the reference epoetin alfa was well tolerated, and the safety profile of each was similar and as expected in patients on dialysis. SC administration of HX575 and the reference epoetin alfa did not elicit the development of neutralizing, clinically relevant antibodies during the 12-month study period and the 6-month safety follow-up period.
